Skip to main content
About us
Our science
Our Pipeline
Partnering
News & Events
Contact
About us
Our science
Our Pipeline
Partnering
News & Events
Contact
In the news
Press releases
Archive
May 6, 2025
Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Apr 1, 2025
Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomodulation at AD/PD™ 2025
Mar 24, 2025
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Upcoming Events
ARVO 2025 Annual Meeting
MAY 4-8, 2025
Bio€quity Europe 2025
MAY 12-14, 2025
Annual Industry Conference in Brain & Cognitive Sciences (ICBCS)
MAY 18, 2025
BIO International Convention 2025
JUNE 16-19, 2025
